Pharmaceutical manufacturer Sigachi Industries has announced a 10 per cent final dividend for FY25 after posting a strong Q4 ...

South Korean pharmaceutical and biotech companies are on track to exceed 10 trillion won ($7.5 billion) in licensing revenues ...

The medium-sized biopharma is showing off new results from dordaviprone and Zepzelca, both of which were acquired through ...

FDA approvals for new biosimilars like Starjemza and Hadlima enhance treatment options, addressing urgent needs for ...

AI will deliver transformative therapies at an exponential scale, addressing the complexities of biology that traditional ...

In the dynamic world of life sciences, companies face unique challenges in safeguarding their valuable assets. From ...

A COPD treatment for former smokers developed by Regeneron Pharmaceuticals and Sanofi failed to meet its primary endpoint in ...

Results released Friday show itepekimab succeeded in one Phase 3 trial but failed in a second, sinking shares of both partner ...

The IgA Nephropathy drugs market is set for 18.1% CAGR growth, led by biologics, FDA approvals, and major pharma R&D efforts ...

We came across a bullish thesis on Bio-Techne Corporation (TECH) on scuttleblurb’s Substack. In this article, we will ...

On May 22, 2025, the FDA approved Bio-Thera Solutions and Hikma Pharmaceuticals’ ustekinumab biosimilar, STARJEMZA® (ustekinumab-hmny) ...